Dividends Calendar Earnings Calendar

SABS | SAB Biotherapeutics

Company profile

  • Industry: Biotechnology
  • Sector: Healthcare
  • Headquarters:   Sioux Falls, South Dakota, United States
  • Number of employees::   143

Company profile

SAB Biotherapeutics is a clinical-stage biopharmaceutical company leveraging its novel DiversitAb™ platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors. By harnessing the native human antibody immune response, SAB's platform enables a scalable and reliable production of these highly-efficacious polyclonal therapies with the potential to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. The Company's lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol, and SAB-176, a multivalent, broadly neutralizing fully-human polyclonal antibody therapeutic candidate designed to bind to Type A and B viruses. Additional pre-clinical product candidates are in development for autoimmune diseases, including SAB-142 for Type 1 Diabetes and organ transplant induction/rejection, and SAB-181 for immune globulin (IgG) mediated diseases.


    2100 East 54th Street North
    Sioux Falls, SD 57104
    United States

      Jump to (Finance sites)

      Support this project

      If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
      More features coming soon :)

      Social Media 

      Recommended Books

      Investing For Dummies
      Buy on Amazon

      In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.